

1 XAVIER BECERRA
Attorney General of California
2 ALEXANDRA M. ALVAREZ
Supervising Deputy Attorney General
3 CHRISTINE A. RHEE
Deputy Attorney General
4 State Bar No. 295656
600 West Broadway, Suite 1800
5 San Diego, CA 92101
P.O. Box 85266
6 San Diego, CA 92186-5266
Telephone: (619) 738-9455
7 Facsimile: (619) 645-2061
8 *Attorneys for Complainant*

FILED
STATE OF CALIFORNIA
MEDICAL BOARD OF CALIFORNIA
SACRAMENTO June 28 2019
BY K. Udong ANALYST

9
10 **BEFORE THE**
PHYSICIAN ASSISTANT BOARD
11 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

12
13 In the Matter of the First Amended Accusation
Against:
14 **GENNADY NOSOVITSKY, P.A.**
15 **12520 Palm Drive**
16 **Desert Hot Springs, CA 92240-4559**
17 **Physician Assistant License No. PA 23278,**
18 Respondent.

Case No. 950-2016-000963
FIRST AMENDED ACCUSATION

19
20 Complainant alleges:

21 **PARTIES**

22 1. Maureen L. Forsyth (Complainant) brings this First Amended Accusation solely in
23 her official capacity as the Executive Officer of the Physician Assistant Board (Board),
24 Department of Consumer Affairs.

25 2. On or about September 27, 2013, the Physician Assistant Board issued Physician
26 Assistant License No. PA 23278 to Gennady Nosovitsky, P.A. (Respondent). Physician Assistant
27 License No. PA 23278 was in full force and effect at all times relevant to the charges brought
28 herein and will expire on February 28, 2021, unless renewed.

JURISDICTION

1
2 3. This First Amended Accusation is brought before the Board under the authority of the
3 following laws. All section references are to the Business and Professions Code (Code) unless
4 otherwise indicated.

5 4. Section 3527 of the Code states, in pertinent part:

6 “(a) The board may order the denial of an application for, or the issuance subject
7 to terms and conditions of, or the suspension or revocation of, or the imposition of
8 probationary conditions upon a physician assistant license after a hearing as required in
9 Section 3528 for unprofessional conduct which includes, but is not limited to, a
10 violation of this chapter, a violation of the Medical Practice Act, or a violation of the
11 regulations adopted by the board or the Medical Board of California.

12 “... ”

13 “(f) The board may order the licensee to pay the costs of monitoring the
14 probationary conditions imposed on the license.

15 “...”

16 5. Section 3528 of the Code states any proceedings involving the denial, suspension or
17 revocation of the application for licensure or the license of a physician assistant, the application
18 for approval or the approval of a supervising physician, or the application for approval or the
19 approval of an approved program under this chapter shall be conducted in accordance with
20 Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government
21 Code.

22 6. Section 2227 of the Code states, in pertinent part:

23 “(a) A licensee whose matter has been heard by an administrative law judge of
24 the Medical Quality Hearing Panel as designated in Section 11371 of the Government
25 Code, or whose default has been entered, and who is found guilty, or who has entered
26 into a stipulation for disciplinary action with the board, may, in accordance with the
27 provisions of this chapter:

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

“(1) Have his or her license revoked upon order of the board.

“(2) Have his or her right to practice suspended for a period not to exceed one year upon order of the board.

“(3) Be placed on probation and be required to pay the costs of probation monitoring upon order of the board.

“(4) Be publicly reprimanded by the board. The public reprimand may include a requirement that the licensee complete relevant educational courses approved by the board.

“(5) Have any other action taken in relation to discipline as part of an order of probation, as the board or an administrative law judge may deem proper.

“...”

7. Section 2234 of the Code states, in pertinent part:

“The board shall take action against any licensee who is charged with unprofessional conduct. In addition to other provisions of this article, unprofessional conduct includes, but is not limited to, the following:

“...”

“(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or omissions. An initial negligent act or omission followed by a separate and distinct departure from the applicable standard of care shall constitute repeated negligent acts.

“(1) An initial negligent diagnosis followed by an act or omission medically appropriate for that negligent diagnosis of the patient shall constitute a single negligent act.

“(2) When the standard of care requires a change in the diagnosis, act, or omission that constitutes the negligent act described in paragraph (1), including, but not limited to, a reevaluation of the diagnosis or a change in treatment, and the licensee’s conduct departs from the applicable standard of care, each departure constitutes a separate and distinct breach of the standard of care.

1 symptoms continued. Respondent gave Patient A two prescriptions for Vyvanse with the
2 instructions to take 40 mg in the morning and 20 mg in the afternoon. Respondent prescribed a
3 one-month supply.

4 12. On or about March 31, 2015, Patient A saw Respondent for a follow up. Patient A
5 reported that she was doing significantly better after taking Vyvanse, but that she was anxious.
6 Respondent discussed Patient A's treatment options and they opted for a trial of Klonopin.
7 Respondent gave Patient A a prescription for Klonopin. He also gave her a refill for Lexapro, a
8 medication Patient A had been taking prior to seeing Respondent.

9 13. On or about April 17, 2015, Patient A saw Respondent for a follow up. According to
10 the progress note, Patient A reported that her ADHD and GAD symptoms had significantly
11 improved. Respondent's plan was to continue prescribing Vyvanse and Klonopin. Respondent
12 noted that care would be transferred to Patient A's private psychiatrist in the future. Respondent
13 gave Patient A a three-month supply of two Vyvanse prescriptions, one for 70 mg capsules, and
14 another for 20 mg capsules. Patient A was to take a 70 mg capsule in the morning, and a 20 mg
15 capsule in the afternoon. Respondent failed to document why he increased Patient A's daily
16 Vyvanse dose from 60 mg to 90 mg, and why he was prescribing 20 mg over the maximum
17 recommended dose.

18 14. On or about June 11, 2015, Patient A returned to see Respondent. Patient A told
19 Respondent that she was waiting to see her psychiatrist in three or four weeks, and was
20 experiencing extreme anxiety over an upcoming exam. Respondent gave Patient A a three-week
21 prescription for Klonopin.

22 15. On or about August 10, 2015, Patient A saw Respondent for a follow up. Respondent
23 noted that Patient A was between insurances and doctor's visits. Respondent gave Patient A a
24 three-month refill for Klonopin. Respondent also gave Patient A a three-month prescription for
25 guanfacine.⁴ Respondent failed to document why he prescribed guanfacine to Patient A rather
26 than Vyvanse.

27 ///

28 ⁴ Guanfacine is a medication used to treat ADHD and high blood pressure.

1 16. On or about September 24, 2015, Patient A saw Respondent for an ADHD follow up.
2 Respondent noted that Patient A was unable to get an appointment with psychiatry for months.
3 He also noted that Patient A's symptoms were re-assessed at this visit and that she was "doing
4 great with the current dose." Nevertheless, Respondent gave Patient A two prescriptions
5 increasing her Vyvanse medications. Patient A was to take a 70 mg capsule in the morning and a
6 60 mg capsule in the afternoon. Respondent failed to document why he switched Patient A back
7 to Vyvanse from guanfacine, and why he increased Patient A's daily dose from 90 mg to 130 mg,
8 which was 60 mg over the maximum recommended dose.

9 17. On or about November 2, 2015, Patient A saw Respondent for a follow up. Patient A
10 told Respondent that she had stopped taking Vyvanse a week and a half prior. She was
11 experiencing significant sleep deprivation from pain associated with a ruptured ovarian cyst.
12 Respondent documented that "it had been reported by patient's peers that she has expressed some
13 irregular behavior." Respondent noted that he had conferred with another physician at the
14 practice, and that he "strongly recommended [Patient A] discontinue [V]yvanse altogether,
15 pending a follow-up with [Patient A]'s psychiatrist."

16 18. Respondent committed negligence his care and treatment of Patient A which includes,
17 but is not limited to, the following: (1) Respondent failed to document why he increased Patient
18 A's Vyvanse dose despite her reports that her symptoms were being effectively managed; and (2)
19 Respondent prescribed Patient A Vyvanse over the maximum recommended dose of 70 mg daily.

20 Patient B

21 19. On or about April 16, 2015, Respondent saw Patient B, a fifty-nine year old male, for
22 a follow up visit. At that time, Patient B had already established care at the clinic where
23 Respondent worked. Patient B was being treated for multiple problems including, but not limited
24 to, depression, human immunodeficiency virus (HIV), type 2 diabetes mellitus, and chronic
25 obstructive pulmonary disease (COPD). Patient B was taking anti-retroviral medications,
26 hypertension medications, medications to manage his diabetes, anti-depressants, and a
27 benzodiazepine. Patient B was a former methamphetamine user. In this visit's progress note,
28 Respondent wrote that Patient B had been diagnosed with ADHD in childhood, but had not yet

1 been treated by the clinic. Respondent wrote that Patient B was experiencing ADHD symptoms,
2 but did not document what those symptoms were, other than saying that Patient B had to drop out
3 of a graduate school class mid-term. Respondent diagnosed Patient B with ADHD and prescribed
4 Vyvanse starting at a 20 mg daily dose. Patient B filled the prescription for 30 capsules of 20 mg
5 Vyvanse on or about April 21, 2015.

6 20. On or about May 14, 2015, Respondent saw Patient B for a medication review and
7 follow up. Patient B reported that he had started taking Vyvanse and that he felt somewhat
8 irritable, but he was also more aware of what was going on around him. Respondent increased
9 Patient B's Vyvanse dose to 40 mg daily.

10 21. On or about May 21, 2015, Respondent saw Patient B for a medication review and
11 follow up. Respondent documented that Patient B was taking 20 mg of Vyvanse in the morning,
12 in contradiction to his previous prescribing instructions to take 40 mg. Respondent wrote that
13 Patient B felt that his focus was improved, but that it was not lasting throughout the day. Once
14 again, Respondent prescribed Vyvanse at a 40 mg daily dose. Patient B filled the prescription for
15 60 capsules of 20 mg Vyvanse on or about May 22, 2015.

16 22. On or about June 4, 2015, Respondent saw Patient B for a follow up. Respondent
17 documented that Patient B was taking 40 mg of Vyvanse in the morning, and that his irritability
18 had decreased. Patient B reported that the effects of the medication wore off around noon to 2
19 p.m., when he noticed he was getting easily distracted. Respondent increased Patient B's daily
20 Vyvanse dose to 40 mg in the morning and 20 mg at 11:30 a.m. or 12:30 p.m.

21 23. On or about June 23, 2015, Respondent saw Patient B for a follow up. Patient B
22 reported that he was doing well on Vyvanse and that he was better able to focus on his
23 homework. Respondent reviewed Patient B's recent visit with an ophthalmologist, in which the
24 ophthalmologist diagnosed Patient B with an amaurosis fugax⁵ in the left eye, which might have
25 resulted from cardiovascular disease. Respondent noted that Patient B was being treated by a
26 cardiologist. Respondent gave Patient B prescriptions for Vyvanse with the instruction to take 40

27 ///

28 ⁵ Amaurosis fugax is a transient loss of vision.

1 mg in the morning and 20 mg in the afternoon. These prescriptions for a one-month supply were
2 filled on or about June 23, 2015 and June 26, 2015.

3 24. On or about August 4, 2015, Patient B filled a prescription for 30 capsules of 40 mg
4 Vyvanse which was written by Respondent. Respondent's records do not include this
5 prescription.

6 25. On or about August 13, 2015, Respondent saw Patient B for a follow up visit.
7 Respondent gave Patient B a 30-day refill for 20 mg Vyvanse, which Patient B filled on or about
8 the same day.

9 26. On or about September 4, 2015, Patient B filled a prescription for 30 capsules of 40
10 mg Vyvanse that was written by Respondent. Respondent's records do not include this
11 prescription.

12 27. On or about September 17, 2015, Patient B filled a prescription for 30 capsules of 20
13 mg Vyvanse that was written by Respondent. Respondent's records do not include this
14 prescription.

15 28. On or about October 21, 2015, Respondent saw Patient B for a follow up. Patient B
16 reported that he was only taking 20 mg of Vyvanse in the morning. Respondent documented that
17 he gave Patient B prescriptions for Vyvanse to last until November 5, 2015, which was when he
18 was receiving his next order of medications. Patient B was to let Respondent know in seven to
19 ten days whether he would take 60 mg or 40 mg daily. Patient B filled prescriptions for 15
20 capsules each of 20 mg and 40 mg Vyvanse on or about the same day.

21 29. On or about November 2, 2015, Patient B filled a prescription for 30 capsules of 60
22 mg Vyvanse that was written by Respondent. Respondent's records do not include this
23 prescription.

24 30. On or about December 2, 2015, Respondent saw Patient B for a follow up.
25 Respondent noted that Patient B was "doing excellent[ly]" on Vyvanse, and was taking 60 mg in
26 the morning and 20 mg at 3:00 p.m. Respondent provided no medical indication or justification
27 for increasing Patient B's daily Vyvanse dose to 80 mg, which is 10 mg above the drug

28 ///

1 manufacturer's maximum daily dose. Patient B filled prescriptions for 30 capsules each of 60 mg
2 and 20 mg Vyvanse on or about the same day.

3 31. On or about December 23, 2015, Respondent saw Patient B for a follow up.
4 Respondent documented that Patient B was taking 80 mg of Vyvanse in the morning,
5 occasionally 20 mg at noon, and 20 mg at 4:00 p.m. for a total of 120 mg per day. Respondent
6 adjusted Patient B's use to 70 mg in the morning and 40 mg at noon. Once again, Respondent
7 provided no medical indication of justification for prescribing 110 mg of Vyvanse daily, which is
8 40 mg above the drug manufacturer's maximum daily dose. Respondent gave Patient B
9 prescriptions for 30 capsules each of 70 mg and 40 mg Vyvanse.

10 32. On or about December 28, 2015, Patient B filled the prescription for 30 capsules of
11 70 mg Vyvanse that was written by Respondent.

12 33. On or about January 6, 2016, Patient B filled the prescription for 30 capsules of 40
13 mg Vyvanse that was written by Respondent.

14 34. On or about February 3, 2016, Patient B filled the prescription for 30 capsules of 70
15 mg Vyvanse that was written by Respondent.

16 35. On or about February 5, 2016, Patient B filled the prescription for 30 capsules of 40
17 mg Vyvanse that was written by Respondent.

18 36. On or about February 12, 2016, Respondent saw Patient B for a follow up.
19 Respondent documented that Patient B's ADHD was "well controlled on current dose of
20 [V]yvanse." Once again, Respondent provided no medical indication of justification for
21 prescribing 110 mg of Vyvanse daily, which is 40 mg above the drug manufacturer's maximum
22 daily dose. He noted that the Vyvanse prescriptions were out of sync by 10 to 14 days.
23 Respondent gave Patient B two prescriptions dated February 14, 2016 for 30 capsules of 70 mg
24 and 40 mg Vyvanse.

25 37. On or about March 4, 2016, April 2, 2016, and May 5, 2016, Patient B continued to
26 fill monthly prescriptions for 30 capsules each of 70 mg and 40 mg Vyvanse, which were written
27 by Respondent.

28 ///

1 38. Respondent committed negligence his care and treatment of Patient B which includes,
2 but is not limited to, the following: (1) Respondent failed to document why he increased Patient
3 B's Vyvanse dose to 110 mg per day; and (2) Respondent prescribed Patient B Vyvanse over the
4 maximum recommended dose of 70 mg daily.

5 **SECOND CAUSE FOR DISCIPLINE**
6 **(Failure to Maintain Adequate and Accurate Records)**


7 39. Respondent has subjected his Physician Assistant License No. PA 23278 to
8 disciplinary action under sections 3527, 2227 and 2266, of the Code, in that he has failed to
9 maintain adequate and accurate records for Patients A and B, as more particularly alleged in
10 paragraphs 11 through 38, above, which are hereby incorporated by reference and re-alleged as if
11 fully set forth herein.

12 **PRAYER**

13 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
14 and that following the hearing, the Physician Assistant Board issue a decision:

- 15 1. Revoking or suspending Physician Assistant License No. PA 23278, issued to
16 Respondent Gennady Nosovitsky, P.A.;
- 17 2. Ordering Respondent Gennady Nosovitsky, P.A., to pay the Physician Assistant
18 Board the reasonable costs of the investigation and enforcement of this case, pursuant to Business
19 and Professions Code section 125.3;
- 20 3. Ordering Respondent Gennady Nosovitsky, P.A., if placed on probation, to pay the
21 Board the costs of probation monitoring pursuant to section 3527, subdivision (f), of the Code;
22 and
- 23 4. Taking such other and further action as deemed necessary and proper.

24
25 DATED: June 28, 2019


26 MAUREEN L. FORSYTH
27 Executive Officer
28 Physician Assistant Board
Department of Consumer Affairs
State of California
Complainant